foscarnet has been researched along with 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Camarasa, MJ; De Clercq, E; Koontz, DL; Lobatón, E; Mellors, JW; Velázquez, S | 1 |
1 other study(ies) available for foscarnet and 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)
| Article | Year |
|---|---|
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
Topics: Cell Extracts; Cell Line, Tumor; Drug Resistance, Viral; Drug Stability; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Hydrolysis; Reverse Transcriptase Inhibitors; Spiro Compounds; Structure-Activity Relationship; Thymidine; Uridine | 2004 |